GCGilles Chatellier

Gilles Chatellier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gilles Chatellier has a total of 196 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Organisational Impact of a Remote Patient Monitoring System for Heart Failure Management: The Experience of 29 Cardiology Departments in France

    by Sarah Alami, Laurène Courouve, Guila Lancman, Pierrette Gomis, Gisele Al-Hamoud, Corinne Laurelli, Hélène Pasche, Gilles Chatellier, Grégoire Mercier, François Roubille, et al.

    Remote patient monitoring (RPM) for the management of patients with chronic heart failure (CHF) has been widely studied from clinical and health-economic points of view. In contrast, data on the organisational impact of this type of RPM are scarce. The objective of the present study of cardiology departments (CDs) in France was to describe the organisational impact of the Chronic Care ConnectTM (CCCTM) RPM system for CHF. An organisational impact map for health technology assessment was used to identify and define the criteria evaluated in the present survey, including the care process, equipment, infrastructure, training, skill transfers, and the stakeholders’ abilities to implement the care process. In April 2021, an online questionnaire was sent to 31 French CDs that were using CCCTM for CHF management: 29 (94%) completed the questionnaire. The survey results showed that CDs progressively modified their organisational structures upon or shortly after the implementation of the RPM device. Twenty-four departments (83%) had created a dedicated team, sixteen (55%) had provided dedicated outpatient consultations for patients with an emergency alert, and twenty-five (86%) admitted patients directly (i.e., avoiding the need to attend the emergency department). The present survey is the first to have assessed the organisational impact of the implementation of the CCCTM RPM device for CHF management. The results highlighted the variety of organisational structures, which tended to structure with the use of the device.


  • Open Access

    Cardiometabolic Disorders and the Risk of Critical COVID-19 as Compared to Influenza Pneumonia

    by Antoine Fayol, Marine Livrozet, Héléna Pereira, Jean-Luc Diehl, David Lebeaux, Jean-Benoit Arlet, Bernard Cholley, Claire Carette, Jean-Baptiste Carves, Sébastien Czernichow, et al.

    We aimed to compare the influence of cardiometabolic disorders on the incidence of severe COVID-19 vs. non-COVID pneumonia. We included all consecutive patients admitted with SARS-CoV-2-positive pneumonia between 12 March 2020 and 1 April 2020 and compared them to patients with influenza pneumonia hospitalized between December 2017 and December 2019 at the same tertiary hospital in Paris. Patients with COVID-19 were significantly younger and more frequently male. In the analysis adjusted for age and sex, patients with COVID-19 were more likely to be obese (adjOR: 2.25; 95% CI 1.24–4.09; p = 0.0076) and receive diuretics (adjOR: 2.13; 95% CI 1.12–4.03; p = 0.021) but were less likely to be smokers (adjOR: 0.40; 95% CI 0.24–0.64; p = 0.0002), have COPD (adjOR: 0.25; 95% CI 0.11–0.56; p = 0.0008), or have a previous or active cancer diagnosis (adjOR: 0.54, 95% CI 0.32–0.91; p = 0.020). The rate of ICU admission was significantly higher in patients with COVID-19 (32.4% vs. 5.2% p < 0.0001). Obesity was significantly associated with the risk of direct ICU admission in patients with COVID-19 but not in patients with influenza pneumonia. Likewise, pre-existing hypertension was significantly associated with mortality in patients with COVID-19 but not in patients with influenza pneumonia. Cardiometabolic disorders differentially influenced the risk of presenting with severe COVID-19 or influenza pneumonia.


  • Open Access

    SPARTE Study: Normalization of Arterial Stiffness and Cardiovascular Events in Patients With Hypertension at Medium to Very High Risk

    by Stephane Laurent, Gilles Chatellier, Michel Azizi, David Calvet, Gabriel Choukroun, Nicolas Danchin, Pascal Delsart, Xavier Girerd, Philippe Gosse, Hakim Khettab, et al.

    The SPARTE study (Strategy for Preventing cardiovascular and renal events based on ARTErial stiffness; URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02617238) is a multicenter open-label randomized controlled trial with blinded end point evaluation, undertaken at 25 French research centers in university hospitals. Patients with primary hypertension were randomly assigned (1:1) to a therapeutic strategy targeting the normalization of carotid-femoral pulse wave velocity (PWV) measured every 6 months (PWV group, n=264) versus a classical therapeutic strategy only implementing the European Guidelines for Hypertension Treatment (conventional group, n=272). In the PWV group, the therapeutic strategy used preferably a combination of ACE (angiotensin-converting enzyme) inhibitor or angiotensin receptor blocker and calcium channel blockers, as well as maximal recommended doses of ACE inhibitors and angiotensin receptor blockers. The primary outcome was a combined end point including particularly stroke and coronary events. Secondary outcomes included the time-course changes in brachial office blood pressure (BP), ambulatory BP, PWV, and treatments. After a median follow-up of 48.3 months, there was no significant between-group difference in primary outcome (hazard ratio, 0.74 [95% CI, 0.40–1.38], P =0.35). In the PWV group, combinations of renin-angiotensin-system blockers and calcium channel blockers were prescribed at higher dosage ( P =0.028), office and ambulatory systolic blood pressure and diastolic blood pressure decreased more ( P P P =0.0003) than in the conventional group. The SPARTE study lacked sufficient statistical power to demonstrate its primary outcome. However, it demonstrated that a PWV-driven treatment for hypertension enables to further reduce office and ambulatory systolic blood pressure and diastolic blood pressure and prevent vascular aging in patients with hypertension at medium-to-very-high risk, compared with strict application of guidelines.


  • Open Access

    Confirmed central olfactory system lesions on brain MRI in COVID-19 patients with anosmia: a case-series

    by Yannick Girardeau, Yoan Gallois, Guillaume De Bonnecaze, Bernard Escudé, Clarisse Lafont, Gilles Chattelier, Mathieu Marx

    Objective: Anosmia has been listed as a key-symptom associated with the COVID-19 infection. Because it often occurs without any sign of rhinitis, lesions of the central olfactory system have been suspected. To date, however, there is no evidence that anosmia caused by SARS-CoV2 could be the result of brain damage. Methods: We conducted a case-series on 10 consecutive COVID-19 patients who reported anosmia. Each patient prospectively underwent a validated olfactory test (Sniffin’ Sticks test) and a brain MRI. Results Hypersignal intensity lesions of the central olfactory system were found in 3 subjects on 3D T2 FLAIR and 2D T2 High Resolution images with a lesion involving the olfactory bulbs and/or the orbitofrontal cortex. These 3 subjects showed a severe and persistent loss of smell on the olfactory test. Mucosal hyperplasia of the upper nasal cavities was found in two other subjects with significant smell disorders. There was no MRI anomaly in two subjects with good smell restoration. Conclusions: Anomalies of the central olfactory system could be responsible for anosmia in patients with COVID-19 infection. Further studies are needed to assess the impact on long-term functional prognosis of these lesions. Key Result: Central anomalies of the olfactory bulb and cortex could be responsible for anosmia in COVID-19 infection


  • Open Access

    Exploration Of The Timeliness Of ICD Codes In Administrative Databases: A Nationwide Study

    by Marie Simon, Bastien Rance, Sandrine Katsahian, Karim Bounebache, Gregoire Rey, Gilles Chatellier, Antoine Neuraz, Anita Burgun, Vincent Looten

    INTRODUCTION: The ICD codes are ubiquitously available in hospital information systems and have been used in a number of areas such as epidemiology, phenotype-genotype association mining, surveillance of the use of drugs and medical devices and health care evaluation. We aimed to analyze the timeliness of the 3-character ICD-10 codes collected in the French national hospital discharge summary database between 2008 and 2017 and we classified the codes according to their evolution. MATERIAL AND METHODS: We extracted all 3-character ICD-10 codes from all French hospital discharge summaries between 2008 and 2017. For each code and by the month, we computed a relative frequency; we also computed the overall amplitude of the study period. Temporal clustering, according to the SAX representation, was performed to classify the main evolution patterns. RESULTS: We extracted 238,334,751 encounters corresponding to 56,621,773 distinct patients. 1,006 ICD codes presented a variation of the relative amplitude of frequencies lower than 50%, 510 codes between 50% and 100% and 521 greater than 100%. Out of the 2,037 codes included in the study, we kept the 1,758 for the temporal clustering. Four clusters were identified, including a global increase and a global decrease patterns. DISCUSSION: The overall results showed a strong instability (i.e. large variation of frequency over time) of the use of ICD codes over time, with an important variation of the relative amplitude of the frequencies. We distinguished between external factors due to changes in billing, organization, policy or regulation and intrinsic factors due to epidemiological phenomenon. The detailed analysis of profiles show that the same cluster can contain profiles influenced by intrinsic epidemiological or external factors or both. Additional knowledge and sources are probably required to determine automatically the origin of the profile.


  • Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial

    by Guy Meyer, Benjamin Besse, Hélène Doubre, Anaïs Charles-Nelson, Sandro Aquilanti, Armine Izadifar, Reza Azarian, Isabelle Monnet, Corinne Lamour, Renaud Descourt, et al.

    The anti-tumour and anti-metastatic properties of heparins have not been tested in patients with early stage cancer. Whether adjuvant low molecular weight heparin (LMWH) tinzaparin impacts the survival of patients with resected non-small cell lung cancer (NSCLC) was investigated.Patients with completely resected stage I, II or IIIA NSCLC were randomly allocated to receive subcutaneous tinzaparin 100 IU·kg−1once a day for 12 weeks or no treatment in addition to standard of care. The trial was open-label with blinded central adjudication of study outcomes. The primary outcome was overall survival.In 549 patients randomised to tinzaparin (n=269) or control (n=280), mean±sdage was 61.6±8.9 years, 190 (34.6%) patients had stage II−III disease, and 220 (40.1%) patients received adjuvant chemotherapy. Median follow-up was 5.7 years. There was no significant difference in overall survival between groups (hazard ratio (HR) 1.24, 95% CI 0.92–1.68; p=0.17). There was no difference in the cumulative incidence of recurrence between groups (subdistribution HR 0.94, 95% CI 0.68–1.30; p=0.70).Adjuvant tinzaparin had no detectable impact on overall and recurrence-free survival of patients with completely resected stage I−IIIA NSCLC. These results do not support further clinical evaluation of LMWHs as anti-tumour agents.


  • Open Access

    Association between borderline dysnatremia and mortality insight into a new data mining approach

    by Yannick Girardeau, Anne-Sophie Jannot, Gilles Chatellier, Olivier Saint-Jean

    Even small variations of serum sodium concentration may be associated with mortality. Our objective was to confirm the impact of borderline dysnatremia for patients admitted to hospital on in-hospital mortality using real life care data from our electronic health record (EHR) and a phenome-wide association analysis (PheWAS). Retrospective observational study based on patient data admitted to Hôpital Européen George Pompidou, between 01/01/2008 and 31/06/2014; including 45,834 patients with serum sodium determinations on admission. We analyzed the association between dysnatremia and in-hospital mortality, using a multivariate logistic regression model to adjust for classical potential confounders. We performed a PheWAS to identify new potential confounders. Hyponatremia and hypernatremia were recorded for 12.0% and 1.0% of hospital stays, respectively. Adjusted odds ratios (ORa) for severe, moderate and borderline hyponatremia were 3.44 (95% CI, 2.41–4.86), 2.48 (95% CI, 1.96–3.13) and 1.98 (95% CI, 1.73–2.28), respectively. ORa for severe, moderate and borderline hypernatremia were 4.07 (95% CI, 2.92–5.62), 4.42 (95% CI, 2.04–9.20) and 3.72 (95% CI, 1.53–8.45), respectively. Borderline hyponatremia (ORa = 1.57 95% CI, 1.35–1.81) and borderline hypernatremia (ORa = 3.47 95% CI, 2.43–4.90) were still associated with in-hospital mortality after adjustment for classical and new confounding factors identified through the PheWAS analysis. Borderline dysnatremia on admission are independently associated with a higher risk of in-hospital mortality. By using medical data automatically collected in EHR and a new data mining approach, we identified new potential confounding factors that were highly associated with both mortality and dysnatremia.


  • Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial

    by Mohamed Bouattour, Eric Assenat, Boris Guiu, Diana Ilonca Alina, Georges-Philippe Pageaux, Annie Sibert, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, et al.

    Background: Sorafenib is the recommended treatment for advanced hepatocellular carcinoma (HCC) but dose-limiting toxicity prevents optimal treatment in a considerable proportion of patients. Large cohort studies have indicated potential efficacy of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres in intermediate and advanced HCC and therefore the SARAH trial was initiated to directly compare the efficacy and safety of SIRT with sorafenib.


  • Open Access

    Leveraging the EHR4CR platform to support patient inclusion in academic studies: challenges and lessons learned

    by Yannick Girardeau, Justin Doods, Eric Zapletal, Gilles Chatellier, Christel Daniel, Anita Burgun, Martin Dugas, Bastien Rance

    The development of Electronic Health Records (EHRs) in hospitals offers the ability to reuse data from patient care activities for clinical research. EHR4CR is a European public-private partnership aiming to develop a computerized platform that enables the re-use of data collected from EHRs over its network. However, the reproducibility of queries may depend on attributes of the local data. Our objective was 1/ to describe the different steps that were achieved in order to use the EHR4CR platform and 2/ to identify the specific issues that could impact the final performance of the platform. We selected three institutional studies covering various medical domains. The studies included a total of 67 inclusion and exclusion criteria and ran in two University Hospitals. We described the steps required to use the EHR4CR platform for a feasibility study. We also defined metrics to assess each of the steps (including criteria complexity, normalization quality, and data completeness of EHRs). We identified 114 distinct medical concepts from a total of 67 eligibility criteria Among the 114 concepts: 23 (20.2%) corresponded to non-structured data (i.e. for which transformation is needed before analysis), 92 (81%) could be mapped to terminologies used in EHR4CR, and 86 (75%) could be mapped to local terminologies. We identified 51 computable criteria following the normalization process. The normalization was considered by experts to be satisfactory or higher for 64.2% (43/67) of the computable criteria. All of the computable criteria could be expressed using the EHR4CR platform. We identified a set of issues that could affect the future results of the platform: (a) the normalization of free-text criteria, (b) the translation into computer-friendly criteria and (c) issues related to the execution of the query to clinical data warehouses. We developed and evaluated metrics to better describe the platforms and their result. These metrics could be used for future reports of Clinical Trial Recruitment Support Systems assessment studies, and provide experts and readers with tools to insure the quality of constructed dataset.


  • Open Access

    Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction (≤40 %) undergoing CABG with cardiopulmonary bypass (LICORN study)

    by Thibaut Caruba, Delphine Hourton, Brigitte Sabatier, Dominique Rousseau, Annick Tibi, Cécile Hoffart-Jourdain, Akim Souag, Nelly Freitas, Mounia Yjjou, Carla Almeida, et al.

    Patients with a left ventricular ejection fraction (LVEF) of less than 40 % are at high risk of developing postoperative low cardiac output syndrome (LCOS). Despite actual treatments (inotropic agents and/or mechanical assist devices), the mortality rate of such patients remains very high (13 to 24 %). The LICORN trial aims at assessing the efficacy of a preoperative infusion of levosimendan in reducing postoperative LCOS in patients with poor LVEF undergoing coronary artery bypass grafting (CABG). LICORN study is a multicenter, randomized double-blind, placebo-controlled trial in parallel groups. 340 patients with LVEF ≤40 %, undergoing CABG will be recruited from 13 French hospitals. The study drug will be started after anaesthesia induction and infused over 24 h (0.1 μg/kg/min). The primary outcome (postoperative LCOS) is evaluated using a composite criterion composed of: 1) need for inotropic agents beyond 24 h following discontinuation of the study drug; 2) need for post-operative mechanical assist devices or failure to wean from these techniques when inserted pre-operatively; 3) need for renal replacement therapy. Secondary outcomes include: 1) mortality at Day 28 and Day 180; 2) each item of the composite criterion of the primary outcome; 3) the number of “ventilator-free” days and “out of intensive care unit” days at Day 28. The usefulness of levosimendan in the perioperative period has not yet been documented with a high level of evidence. The LICORN study is the first randomized controlled trial evaluating the clinical value of preoperative levosimendan in high risk cardiac surgical patients undergoing CABG. NCT02184819 (ClinicalTrials.gov).